REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Philgen Pharmaceuticals Inc. (Philippines)

Main Activities: Other Miscellaneous Nondurable Goods Merchant Wholesalers
Full name: Philgen Pharmaceuticals Inc. Profile Updated: December 23, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Philgen Pharmaceuticals Inc. is a company in Philippines, with a head office in Mandaluyong. It operates in the Other Miscellaneous Nondurable Goods Merchant Wholesalers industry. The company was established on June 08, 2018. The company’s latest financial report indicates a net sales revenue increase of 296.86% in 2023. A growth of 105.29% was recorded in its total assets. In, 2023, the company’s net profit margin increased by 0.77%.

Headquarters
151 San Francisco Street Barangay Plainview
Mandaluyong; National Capital Region; Postal Code: 1550

Contact Details: Purchase the Philgen Pharmaceuticals Inc. report to view the information.

Basic Information
Financial Auditors:
Purchase the Philgen Pharmaceuticals Inc. report to view the information.
Incorporation Date:
June 08, 2018
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Company Performance
Financial values in the chart are available after Philgen Pharmaceuticals Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PHP. Absolute financial data is included in the purchased report.
Net sales revenue
296.86%▲
Total Operating Revenue
296.86%▲
Operating Profit
391.67%▲
EBITDA
366.95%▲
Net Profit/Loss for the Period
360.94%▲
Total Assets
105.29%▲
Total Equity
94.08%▲
Operating Profit Margin
1.43%▲
Net Profit Margin
0.77%▲
Return on Equity (ROE)
28.07%▲
Quick Ratio
2.08%▲
Cash Ratio
1.06%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo